Shattuck Labs Announces Participation in Upcoming December Conferences
Shattuck Labs Announces Participation in Upcoming December Conferences
A live webcast of the presentation and fireside chat will be available on the Investors section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced that company management will participate in two investor conferences in December 2024.
德克薩斯州奧斯汀和北卡羅來納州達勒姆，2024年11月25日（GLOBE NEWSWIRE）——生物技術公司Shattuck Labs, Inc.（Shattuck）（納斯達克股票代碼：STTK）是一家率先開發用於治療癌症和慢性免疫相關疾病患者的針對腫瘤壞死因子（TNF）超家族受體的新療法的生物技術公司，今天宣佈，公司管理層將參加2024年12月的兩次投資者會議。
Presentation Details
Conference: Piper Sandler 36th Annual Healthcare Conference
Format: Corporate Presentation
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: December 3, 2024
Time: 12:30 p.m. ET
演示詳情
會議：派珀·桑德勒第 36 屆年度醫療保健會議
格式：企業演示文稿
主持人：泰勒·施雷伯萬博士，博士，沙特克首席執行官
日期：2024 年 12 月 3 日
時間：美國東部時間下午 12:30
Conference: Evercore 7th Annual HealthCONx Conference
Format: Fireside chat with covering analyst, Jonathan Miller, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: December 4, 2024
Time: 8:45 a.m. ET
會議：Evercore 第七屆年度 HealthConx 會議
格式：與封面分析師喬納森·米勒博士的爐邊談話
主持人：泰勒·施雷伯萬博士，博士，沙特克首席執行官
日期：2024 年 12 月 4 日
時間：美國東部時間上午 8:45
A live webcast of the presentation and fireside chat will be available on the Investors section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.
公司網站的 「投資者」 部分將提供演講和爐邊談話的網絡直播。網絡直播的重播將在演講之日後最長存檔90天。
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases and cancer. The Company is developing a potentially first-in-class antibody for the treatment of IBD and other inflammatory autoimmune diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .
關於 Shattuck Labs, Inc.
Shattuck Labs, Inc.（納斯達克股票代碼：STTK）是一家生物技術公司，專門開發自身免疫/炎症性疾病和癌症的潛在治療方法。該公司正在開發一種可能用於治療IBD和其他炎症性自身免疫性疾病的同類首創抗體。Shattuck在蛋白質工程和新型腫瘤壞死因子受體激動劑和拮抗劑療法開發方面的專業知識彙集在其主導項目 SL-325 中，這是一款同類首款DR3拮抗劑抗體，旨在更全面地阻斷臨床驗證的TL1A/DR3途徑。該公司在德克薩斯州的奧斯汀和北卡羅來納州的達勒姆都設有辦事處。欲了解更多信息，請訪問:.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
公司打算使用其網站的投資者關係部分作爲披露重大非公開信息以及遵守FD法規規定的披露義務的手段。
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
投資者和媒體聯繫人：
康納·理查森
投資者關係副總裁
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
